## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.5% in lower entry zone (4.0-10.0%), top quartile (83rd pct) cross-sectional ranking. Caution: MRS_5 (-0.8%) diverging from MRS_20, watch for reversal. Outperforming sector by 9.0%. Caution: momentum weakening (-3.6% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($78.53)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. 18,934 Shares in GE HealthCare Technologies Inc. $GEHC Bought by London & Capital Asset Management Ltd**
- Source: MarketBeat | 20251209T131728 | Bullish | Relevance: 99%
-  London & Capital Asset Management Ltd recently acquired 18,934 shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the second quarter, valued at approximately $1.4 million. Several other institutional investors have also adjusted their holdings in GEHC, indicating significant institutional interest. The company recently reported its quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**2. New Healthcare Leaders Emerge. 3 Stocks With Bullish Charts.**
- Source: Barron's | 20251209T160812 | Bullish | Relevance: 99%
- Several non-biotech healthcare stocks are showing significant momentum, breaking out of bases and establishing themselves as sector leaders. These medical technology, services, and equipment stocks, including GE Healthcare, STERIS, and Hinge Health (mentioned in the original article title), exhibit improving volume patterns, accelerating relative strength, and clean technical setups. This strong performance indicates they are well-positioned to continue their upward trend in the coming weeks.

**3. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: Business Wire | 20251209T150810 | Bullish | Relevance: 99%
- The AI-Powered Medical Devices Market is projected to reach $59.8 billion by 2032, growing at an 18.26% CAGR from $18.36 billion in 2025. This growth is driven by technological advancements, increasing adoption in clinical settings, and supportive reimbursement frameworks. Key players include GE HealthCare, Siemens Healthineers, and Philips, with AI integrating across all stages of device lifecycle to enhance diagnostics, monitoring, and treatment.

**4. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: The AI Journal | 20251209T150812 | Bullish | Relevance: 98%
- The AI-powered medical devices market is projected to reach $59.84 billion by 2032, growing at a CAGR of 18.26% from $15.64 billion in 2024. This growth is driven by technological integration and expanded adoption across clinical environments, with key players including GE HealthCare Technologies, Siemens Healthineers, and Philips. The report highlights AI's role in diagnostics, monitoring, and treatment, emphasizing its impact on medical workflows and operational efficiency.

**5. GE HealthCare, Mayo Clinic expand partnership around radiology research**
- Source: MedTech Dive | 20251209T161709 | Bullish | Relevance: 98%
-  GE HealthCare and Mayo Clinic have expanded their partnership, called GEMINI-RT, to personalize radiation therapy and cancer care through the integration of imaging, AI, and patient monitoring. The collaboration aims to move away from a "one-size-fits-all" approach by optimizing radiation doses based on individual patient data and monitoring for early side effects. This five-year initiative will explore clinical trials and integrate innovations into GE HealthCare's product portfolio globally.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.8 |
| Current P/E | 18.3 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.0% to 4.5% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 83rd percentile. MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.7% shows strong absolute momentum above own 20MA. Outperforming sector by 9.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.69), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.46% (CS: 83) | Strong |
| RSI_14 | 62.8 | Neutral |
| MACD Histogram | 0.69 | Bullish |
| vs SMA20 | 1.067x | Above |
| vs SMA50 | 1.090x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $83.03
- **Stop Loss:** $78.53 (5.4% risk)
- **Target:** $89.78 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $5,479.98
- **Portfolio %:** 5.48%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*